PLYMOUTH, Minn. and REDWOOD CITY, Calif., Sept. 4 /PRNewswire-FirstCall/-- ev3 Inc. (Nasdaq: EVVV) and FoxHollow Technologies, Inc. (Nasdaq: FOXH)announced today that FoxHollow has set October 4, 2007 as the date of thespecial meeting of FoxHollow stockholders to vote on the proposed merger withev3. The record date for determining stockholders entitled to vote at thespecial meeting was the close of business on August 30, 2007. FoxHollow andev3 anticipate mailing the information/proxy statement-prospectus to theirstockholders on or about September 5, 2007. The special meeting will be heldon October 4, 2007 at 9:00 a.m., local time, at 900 Chesapeake Drive, RedwoodCity, CA 94063.
The registration statement on Form S-4 containing the information/proxystatement-prospectus related to the proposed merger was declared effective bythe Securities and Exchange Commission on August 30, 2007.
Assuming the FoxHollow stockholders approve the merger agreement at thespecial meeting on October 4, 2007, ev3 and FoxHollow would anticipatecompleting the merger on or about October 5, 2007.
About ev3 Inc.
ev3 Inc. is a global medical device company focused on endovasculartechnologies for the minimally invasive treatment of vascular diseases anddisorders.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S.and other countries.
All trademarks and trade names referred to in this press release are theproperty of their respective owners.
About FoxHollow Technologies
FoxHollow Technologies, Inc. develops and markets minimally invasivedevices for the removal of plaque and thrombus for the treatment of peripheralartery disease (PAD). PAD results from plaque that accumulates in the arteriesand blocks blood flow in the legs. These blockages can result in severe painfor patients and very limited physical mobility. The company's SilverHawkPlaque Excision System is a minimally invasive method of removing theobstructive plaque and restoring blood flow to the legs and feet. Thecompany's Rinspirator thrombectomy system removes thrombus, or blood clots,from occluded arteries in patients suffering from PAD or coronary arterydisease.
This press release contains "forward-looking statements" about ev3 andFoxHollow within the meaning of the Private Securities Litigation Reform Actof 1995. Such statements include, but are not limited to, statements about thedistribution of the information/proxy statement-prospectus, the expectedtiming of the completion of the stockholder meeting, and completion of themerger involving ev3 and FoxHollow and other statements identified by wordssuch as "anticipate," "believe," "plan," "estimate," "expect," "intend,""will," "should," "may," or words of similar meaning and any other statementsthat are not historical facts. Such forward-looking statements are based uponthe current beliefs and expectations of ev3's and FoxHollow's management andare inherently subject to significant business, economic and competitiveuncertainties and contingencies, many of which are difficult to predict andgenerally beyond the control of ev3 and FoxHollow.
The following factors, among others, could cause actual results to differmaterially from the anticipated results or other expectations expressed in theforward-looking statement: the failure of FoxHollow stockholders to approvethe transaction, the inability to satisfy the closing conditions contained inthe merger agreement executed by ev3 and FoxHollow, and other extraordinarycircumstances outside the control of ev3 or FoxHollow. Additional factors thatcould cause ev3's and FoxHollow's results to differ materially from thosedescribed in the forward-looking statements can be found in the registrationstatement on Form S-4 that ev3 filed on August 17, 2007 (and any amendmentsand supplements thereto), ev3's and FoxHo